New drug candidates target root cause of COPD by activating cellular defense system

Researchers compared two classes of experimental drugs for COPD, both designed to activate Nrf2—a master switch that protects lung cells from oxidative damage. The work could accelerate development of the first treatments that address COPD's underlying biology rather than just managing symptoms, potentially opening a significant new market.

Originaltitel: Targeting the Keap1-Nrf2 Axis in COPD: Comparative analysis of electrophilic and peptide-based Nrf2 activators in airway and immune cells